ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 114 filers reported holding ESPERION THERAPEUTICS INC NE in Q4 2015. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $41,957,000 | +8.3% | 837,125 | 0.0% | 6.89% | +3.9% |
| Q2 2017 | $38,742,000 | +31.1% | 837,125 | 0.0% | 6.64% | +23.3% |
| Q1 2017 | $29,559,000 | +44.2% | 837,125 | -48.9% | 5.38% | +12.9% |
| Q4 2016 | $20,497,000 | -9.6% | 1,637,125 | 0.0% | 4.76% | +2.0% |
| Q3 2016 | $22,674,000 | +40.2% | 1,637,125 | 0.0% | 4.67% | +22.3% |
| Q2 2016 | $16,175,000 | -41.6% | 1,637,125 | 0.0% | 3.82% | -31.1% |
| Q1 2016 | $27,684,000 | -24.0% | 1,637,125 | 0.0% | 5.54% | -11.8% |
| Q4 2015 | $36,442,000 | -5.6% | 1,637,125 | 0.0% | 6.28% | -7.4% |
| Q3 2015 | $38,620,000 | -71.1% | 1,637,125 | 0.0% | 6.79% | -65.9% |
| Q2 2015 | $133,851,000 | -29.6% | 1,637,125 | -20.3% | 19.93% | -19.9% |
| Q1 2015 | $190,255,000 | +129.0% | 2,054,594 | 0.0% | 24.90% | +97.7% |
| Q4 2014 | $83,088,000 | +65.3% | 2,054,594 | 0.0% | 12.60% | +29.2% |
| Q3 2014 | $50,260,000 | +54.5% | 2,054,594 | 0.0% | 9.75% | +3.6% |
| Q2 2014 | $32,540,000 | – | 2,054,594 | – | 9.40% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $27,840,842 | 18.82% |
| Ikarian Capital, LLC | 1,891,147 | $11,781,846 | 2.84% |
| Altium Capital Management LP | 620,000 | $3,862,600 | 1.96% |
| Ikarian Capital, LLC | 1,296,900 | $8,079,687 | 1.95% |
| Parkman Healthcare Partners LLC | 822,784 | $5,125,944 | 1.36% |
| Deep Track Capital, LP | 4,000,000 | $24,920,000 | 1.05% |
| Monaco Asset Management SAM | 470,100 | $2,928,723 | 0.88% |
| BRAIDWELL LP | 3,393,405 | $21,140,913 | 0.71% |
| Telemetry Investments, L.L.C. | 71,000 | $442 | 0.70% |
| Rhenman & Partners Asset Management AB | 900,000 | $5,607,000 | 0.58% |